Compare Cipla with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES PHARMA SCIENCE - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES PHARMA SCIENCE CIPLA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 30.6 -7.4 - View Chart
P/BV x 4.3 1.0 430.5% View Chart
Dividend Yield % 0.5 0.8 63.3%  

Financials

 CIPLA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    CIPLA
Mar-21
STRIDES PHARMA SCIENCE
Mar-21
CIPLA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8791,000 87.9%   
Low Rs411304 135.1%   
Sales per share (Unadj.) Rs237.6369.7 64.3%  
Earnings per share (Unadj.) Rs29.839.6 75.1%  
Cash flow per share (Unadj.) Rs43.062.6 68.7%  
Dividends per share (Unadj.) Rs5.002.50 200.0%  
Avg Dividend yield %0.80.4 202.3%  
Book value per share (Unadj.) Rs226.7309.1 73.4%  
Shares outstanding (eoy) m806.4689.68 899.3%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.71.8 153.9%   
Avg P/E ratio x21.616.4 131.6%  
P/CF ratio (eoy) x15.010.4 144.0%  
Price / Book Value ratio x2.82.1 134.8%  
Dividend payout %16.86.3 266.3%   
Avg Mkt Cap Rs m519,82658,465 889.1%   
No. of employees `000NANA-   
Total wages/salary Rs m32,5185,501 591.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m191,59633,159 577.8%  
Other income Rs m2,698734 367.6%   
Total revenues Rs m194,29433,893 573.3%   
Gross profit Rs m42,4876,702 634.0%  
Depreciation Rs m10,6772,063 517.6%   
Interest Rs m1,6071,501 107.1%   
Profit before tax Rs m32,9013,872 849.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,888317 2,808.0%   
Profit after tax Rs m24,0133,555 675.4%  
Gross profit margin %22.220.2 109.7%  
Effective tax rate %27.08.2 330.5%   
Net profit margin %12.510.7 116.9%  
BALANCE SHEET DATA
Current assets Rs m132,09528,172 468.9%   
Current liabilities Rs m45,91627,383 167.7%   
Net working cap to sales %45.02.4 1,890.7%  
Current ratio x2.91.0 279.6%  
Inventory Days Days68165 41.0%  
Debtors Days Days7122 5.4%  
Net fixed assets Rs m116,27739,996 290.7%   
Share capital Rs m1,613897 179.8%   
"Free" reserves Rs m181,23226,823 675.7%   
Net worth Rs m182,84427,719 659.6%   
Long term debt Rs m12,0288,826 136.3%   
Total assets Rs m248,37268,168 364.4%  
Interest coverage x21.53.6 599.8%   
Debt to equity ratio x0.10.3 20.7%  
Sales to assets ratio x0.80.5 158.6%   
Return on assets %10.37.4 139.1%  
Return on equity %13.112.8 102.4%  
Return on capital %17.714.7 120.5%  
Exports to sales %31.351.1 61.2%   
Imports to sales %10.90-   
Exports (fob) Rs m59,95116,941 353.9%   
Imports (cif) Rs m20,911NA-   
Fx inflow Rs m68,05135,084 194.0%   
Fx outflow Rs m20,911392 5,335.8%   
Net fx Rs m47,14034,692 135.9%   
CASH FLOW
From Operations Rs m37,5524,814 780.0%  
From Investments Rs m-23,872-5,208 458.3%  
From Financial Activity Rs m-13,299-158 8,419.2%  
Net Cashflow Rs m509-564 -90.3%  

Share Holding

Indian Promoters % 13.5 30.3 44.5%  
Foreign collaborators % 20.1 0.3 7,459.3%  
Indian inst/Mut Fund % 48.6 38.5 126.4%  
FIIs % 26.6 19.7 135.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 69.4 95.6%  
Shareholders   418,584 133,190 314.3%  
Pledged promoter(s) holding % 0.0 57.2 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    



Today's Market

Sensex, Nifty End Marginally Lower; Metal Stocks Witness Selling(Closing)

After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

The Most Oversold Stocks in India. Is it Finally Time to Get in? (Views On News)

Jan 7, 2022

With the help of relative strength index (RSI), we take a look at top stocks that are oversold at current levels.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


May 23, 2022 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS